1,257,243 Shares in Aldeyra Therapeutics, Inc. $ALDX Purchased by BlackRock Inc.

Key Points

• BlackRock acquired 1,257,243 shares of Aldeyra Therapeutics in the second quarter, valued at approximately $2.68 million and representing a 2.08% stake.
• Aldeyra’s stock opened at $1.48, near its 52-week low of $1.07 and well below its 52-week high of $5.93. Institutional investors collectively own 59.71% of the company.
• Analyst sentiment is mixed, with one Buy, one Hold and one Sell rating; the consensus rating is Hold with a $5.50 price target. The company reported a quarterly loss of $0.09 per share, in line with estimates.

BlackRock Inc. acquired a new position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,257,243 shares of the biotechnology company's stock, valued at approximately $2,678,000. BlackRock Inc. owned 2.08% of Aldeyra Therapeutics at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Global Retirement Partners LLC purchased a new position in shares of Aldeyra Therapeutics in the 4th quarter valued at approximately $52,000. CIBC Private Wealth Group LLC bought a new stake in shares of Aldeyra Therapeutics during the 3rd quarter valued at $55,000. BNP Paribas Financial Markets boosted its holdings in shares of Aldeyra Therapeutics by 36.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company's stock valued at $55,000 after buying an additional 2,859 shares in the last quarter. Federation des caisses Desjardins du Quebec boosted its holdings in shares of Aldeyra Therapeutics by 25.8% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 12,187 shares of the biotechnology company's stock valued at $63,000 after buying an additional 2,500 shares in the last quarter. Finally, Caption Management LLC grew its position in shares of Aldeyra Therapeutics by 110.6% in the 2nd quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company's stock worth $49,000 after buying an additional 132,358 shares during the period. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Price Performance

NASDAQ:ALDX opened at $1.48 on Friday. The stock has a market cap of $89.29 million, a price-to-earnings ratio of -3.79 and a beta of 1.20. The company's 50 day moving average price is $1.71 and its 200-day moving average price is $2.20. Aldeyra Therapeutics, Inc. has a 52 week low of $1.07 and a 52 week high of $5.93.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.09). As a group, sell-side analysts anticipate that Aldeyra Therapeutics, Inc. will post -0.39 earnings per share for the current year.

Analyst Ratings Changes

ALDX has been the subject of a number of recent research reports. Wall Street Zen cut shares of Aldeyra Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Weiss Ratings upgraded shares of Aldeyra Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, August 31st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Aldeyra Therapeutics presently has an average rating of "Hold" and a consensus price target of $5.50.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company's research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company's lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.